Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in pituicytes/fscs | 0.75 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 3321
Sealed predictions
- ZDHHC9 in dopamine neurons, braak+0.17 (p 0.655) → +0.11 (p 0.785)receipt 3328
- ZDHHC9 in oligodendrocytes, braak+0.04 (p 0.928) → +0.03 (p 0.946)receipt 3327
Swarm cases
receipt 3328: ZDHHC9 in dopamine neurons, braak
- power
- full sample +0.12 (p 0.646, n 18), 95% CI -0.37 to +0.55. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.02 (p 0.928, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.01 (p 0.983, n 18). could be the mix.
- skeptic
- leave-one-out range -0.01 to +0.28, sign flips 1; without severely affected donors +0.12 (p 0.646, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ZDHHC9 in dopamine neurons.
case closed: nothing better to follow up.
receipt 3327: ZDHHC9 in oligodendrocytes, braak
- power
- full sample +0.09 (p 0.722, n 18), 95% CI -0.39 to +0.53. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.10 (p 0.702, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.06 (p 0.814, n 18). could be the mix.
- skeptic
- leave-one-out range -0.02 to +0.23, sign flips 2; without severely affected donors +0.09 (p 0.722, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ZDHHC9 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts